Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lower patients' cholesterol now.

× No keyword cloud information.

8 in total

Review 1. The value of lowering cholesterol after myocardial infarction.

Authors: J E Rossouw; B Lewis; B M Rifkind
Journal: N Engl J Med Date: 1990-10-18 Impact factor: 91.245

2. Cholesterol and total mortality: need for larger trials.

Authors: R Collins; A Keech; R Peto; P Sleight; J Kjekshus; L Wilhelmsen; S MacMahon; J Shaw; J Simes; E Braunwald
Journal: BMJ Date: 1992-06-27

Review 3. Might treatment of hypercholesterolaemia increase non-cardiac mortality?

Authors: M F Oliver
Journal: Lancet Date: 1991-06-22 Impact factor: 79.321

4. Pravastatin, lipids, and major coronary events.

Authors: C D Furberg; R P Byington; J R Crouse; M A Espeland
Journal: Am J Cardiol Date: 1994-06-01 Impact factor: 2.778

Review 5. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

Authors: K Pyörälä; G De Backer; I Graham; P Poole-Wilson; D Wood
Journal: Eur Heart J Date: 1994-10 Impact factor: 29.983

6. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

Authors: D Waters; L Higginson; P Gladstone; B Kimball; M Le May; S J Boccuzzi; J Lespérance
Journal: Circulation Date: 1994-03 Impact factor: 29.690

7. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

Authors: C D Furberg; H P Adams; W B Applegate; R P Byington; M A Espeland; T Hartwell; D B Hunninghake; D S Lefkowitz; J Probstfield; W A Riley
Journal: Circulation Date: 1994-10 Impact factor: 29.690

8. Cholesterol lowering and mortality: the importance of considering initial level of risk.

Authors: G D Smith; F Song; T A Sheldon
Journal: BMJ Date: 1993-05-22

8 in total

12 in total

Review 5. Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement.

Authors: M Pringle
Journal: BMJ Date: 1998-10-24

10. The cost-effectiveness of lipid lowering in patients with ischaemic heart disease: an intervention and evaluation in primary care.

Authors: J Hippisley-Cox; M Pringle
Journal: Br J Gen Pract Date: 2000-09 Impact factor: 5.386

Lower patients' cholesterol now.

Review 1. The value of lowering cholesterol after myocardial infarction.

2. Cholesterol and total mortality: need for larger trials.

Review 3. Might treatment of hypercholesterolaemia increase non-cardiac mortality?

4. Pravastatin, lipids, and major coronary events.

Review 5. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

6. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

8. Cholesterol lowering and mortality: the importance of considering initial level of risk.

Review 1. Risk factor thresholds: their existence under scrutiny.

2. Lowering patients' cholesterol. Few eligible patients currently receive treatment.

3. Lowering patients' cholesterol. Extrapolating results of trial of simvastatin gives room for doubt.

4. Lowering patients' cholesterol. Excluding patients from trials increases uncertainty.

Review 5. Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement.

Review 6. Communicating the risk reduction achieved by cholesterol reducing drugs.

7. The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing evidence-based treatment.

8. Interventions in OXCHECK study waste resources.

9. Beneficial effects of simvastatin may be due to non-lipid actions.

10. The cost-effectiveness of lipid lowering in patients with ischaemic heart disease: an intervention and evaluation in primary care.